Bone-sparing properties of oral contraceptives
review
OA: closed
CC0
AI-generated summary
This paper investigates the bone-sparing properties of oral contraceptives.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Postmenopausal osteoporosis is a major health care problem that affects 20 million women in the United States and accounts for > 1 million fractures per year. Hormone replacement therapy is effective for reducing bone loss in the postmenopausal women. However, intervention before menopause may delay or prevent the decline in bone mass that begins between ages 30 and 40 years. The effects of oral contraceptives on bone mass have been investigated, and a positive association between oral contraceptive use and bone mass that is directly related to the duration of oral contraceptive use was observed. The effects of oral contraceptives on bone mass may be related to the specific formation. The effect of estrogens is dose related, and the optimal dose appears to be 25 to 35 micrograms of ethinyl estradiol or its equivalent. Results from several studies show that norethindrone has a positive effect on bone mass. An oral contraceptive may offer optimal birth control for the older premenopausal woman who currently uses other forms of birth control.
My notes (saved in your browser only)
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (4)
- Is It Possible to Prevent Bone Loss in Young Women Treated with Luteinizing Hormone-Releasing Hormone Agonists? 1990
- The effects of combining norethindrone with a gonadotropin-releasing hormone agonist in the treatment of symptomatic endometriosis 1990
- The effects of combining norethindrone with a gonadotropin‐releasing hormone agonist in the treatment of symptomatic endometriosis 1990
- A randomized double blind placebo controlled trial of the effects on bone metabolism of the combination of nafarelin acetate and norethisterone 1992
References (30)
- A randomized double blind placebo controlled trial of the effects on bone metabolism of the combination of nafarelin acetate and norethisterone via openalex
- Is It Possible to Prevent Bone Loss in Young Women Treated with Luteinizing Hormone-Releasing Hormone Agonists? via openalex
- The effects of combining norethindrone with a gonadotropin-releasing hormone agonist in the treatment of symptomatic endometriosis via openalex
- The effects of combining norethindrone with a gonadotropin‐releasing hormone agonist in the treatment of symptomatic endometriosis via openalex
- W2010523186 via openalex
- W2015950286 via openalex
- W2020147600 via openalex
- W2030066907 via openalex
- W2047366838 via openalex
- W2067058076 via openalex
- W2068011646 via openalex
- W2073742942 via openalex
- W2084587826 via openalex
- W2107314134 via openalex
- W2117193676 via openalex
- W2148707842 via openalex
- W2157317148 via openalex
- W2161500703 via openalex
- W2293102176 via openalex
- W2338482410 via openalex
- W2339861034 via openalex
- W2340796618 via openalex
- W3022017015 via openalex
- W6601849366 via openalex
- W6697277409 via openalex
- W43666124 via openalex
- W6703760808 via openalex
- W1928979506 via openalex
- W1968327793 via openalex
- W1989131241 via openalex
SciLite annotations
organisms 2
noordeloos 2009062
noordeloos 2009062
chemicals 4
hormone
estrone
estradiol
norethisterone
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- scilite
- last seen: 2026-05-18T04:57:49.680383+00:00
License: CC0
· commercial use OK